Magali Rebucci-Peixoto

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Stéfano Kim, Bruno Buecher, Thierry André et al. · BMC Cancer · 2020 · 27 citations · Full text

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotévi et al. · Frontiers in Oncology · 2022 · 26 citations · Full text

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto et al. · BMC Cancer · 2023 · 21 citations · Full text